Terms: = Cervical cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
254 results:
1. Clonal origin and genomic diversity in Lynch syndrome-associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of MLH1 p.L582H.
Takahashi K; Yachida N; Tamura R; Adachi S; Kondo S; Abé T; Umezu H; Nyuzuki H; Okuda S; Nakaoka H; Yoshihara K
Genes Chromosomes Cancer; 2024 Mar; 63(3):e23231. PubMed ID: 38459936
[TBL] [Abstract] [Full Text] [Related]
2. Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms.
Heydarnia E; Dorostgou Z; Hedayati N; Mousavi V; Yahyazadeh S; Alimohammadi M; Gheibi M; Heidari P; Igder S; Mafi A; Vakili O
Cell Commun Signal; 2024 Feb; 22(1):107. PubMed ID: 38341592
[TBL] [Abstract] [Full Text] [Related]
3. Exploring a novel seven-gene marker and mitochondrial gene TMEM38A for predicting cervical cancer radiotherapy sensitivity using machine learning algorithms.
Wang J; Mou X; Lu H; Jiang H; Xian Y; Wei X; Huang Z; Tang S; Cen H; Dong M; Liang Y; Shi G
Front Endocrinol (Lausanne); 2023; 14():1302074. PubMed ID: 38327905
[TBL] [Abstract] [Full Text] [Related]
4. Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer.
Zhou J; Li H; Wu B; Zhu L; Huang Q; Guo Z; He Q; Wang L; Peng X; Guo T
Sci Rep; 2024 Jan; 14(1):1860. PubMed ID: 38253629
[TBL] [Abstract] [Full Text] [Related]
5. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
Chen J; Pang L; He L; Li T; Cheng X
Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
[TBL] [Abstract] [Full Text] [Related]
6. DHCR7 promotes lymph node metastasis in cervical cancer through cholesterol reprogramming-mediated activation of the KANK4/pi3k/AKT axis and VEGF-C secretion.
Mei X; Xiong J; Liu J; Huang A; Zhu D; Huang Y; Wang H
Cancer Lett; 2024 Mar; 584():216609. PubMed ID: 38211648
[TBL] [Abstract] [Full Text] [Related]
7. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/pi3k Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
8. The effects of HPV oncoproteins on host communication networks: Therapeutic connotations.
Skelin J; Luk HY; Butorac D; Boon SS; Tomaić V
J Med Virol; 2023 Dec; 95(12):e29315. PubMed ID: 38115222
[TBL] [Abstract] [Full Text] [Related]
9. HPV E6/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor.
Peng Q; Wang L; Zuo L; Gao S; Jiang X; Han Y; Lin J; Peng M; Wu N; Tang Y; Tian H; Zhou Y; Liao Q
Cancer Gene Ther; 2024 Jan; 31(1):9-17. PubMed ID: 38102462
[TBL] [Abstract] [Full Text] [Related]
10. Design, synthesis and bioevaluation of novel prenylated chalcones derivatives as potential antitumor agents.
Yu J; Wang X; Cheng S; Zeng X; Wan X; Wei S; Xu B; Luo H; Meng X
Eur J Pharm Sci; 2024 Jan; 192():106660. PubMed ID: 38052256
[TBL] [Abstract] [Full Text] [Related]
11. High-grade intraductal carcinoma of the parotid gland harboring CTNNA1::ALK rearrangement: Changes in genetic status using genetic testing during treatment with an ALK inhibitor.
Watanabe T; Honma Y; Yonemori K; Sunami K; Yoshimoto S; Mori T
Head Neck; 2024 Mar; 46(3):E26-E31. PubMed ID: 38018800
[TBL] [Abstract] [Full Text] [Related]
12. Revisiting the role of endogenous STAT3 in HPV-positive cervical cancer cells.
Strobel TD; Weber M; Heber N; Holzer A; Hoppe-Seyler K; Hoppe-Seyler F
J Med Virol; 2023 Nov; 95(11):e29230. PubMed ID: 38009614
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
14. The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance.
Wang M; Liu J; Liao X; Yi Y; Xue Y; Yang L; Cheng H; Liu P
Redox Biol; 2023 Nov; 67():102931. PubMed ID: 37866161
[TBL] [Abstract] [Full Text] [Related]
15. The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
Wolf CL; Pruett C; Lighter D; Jorcyk CL
Front Immunol; 2023; 14():1239732. PubMed ID: 37841259
[TBL] [Abstract] [Full Text] [Related]
16. Transglutaminase 3 suppresses proliferation and cisplatin resistance of cervical cancer cells by inactivation of the pi3k/AKT pathway.
Chen R; Fang T; Liu N; Shi X; Wang J; Yu H
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2269-2280. PubMed ID: 37812238
[TBL] [Abstract] [Full Text] [Related]
17. Prevalence and Prognostic Significance of pik3ca Mutation and CNV Status and Phosphorylated AKT Expression in Patients With cervical cancer Treated With Primary Surgery.
Martell K; McIntyre JB; Abedin T; Kornaga EN; Chan AMY; Enwere E; Köbel M; Dean ML; Phan T; Ghatage P; Lees-Miller SP; Doll CM
Int J Gynecol Pathol; 2024 Mar; 43(2):158-170. PubMed ID: 37668363
[TBL] [Abstract] [Full Text] [Related]
18. RAIDS atlas of significant genetic and protein biomarkers in cervical cancer.
Scholl S; Roufai DB; Chérif LL; Kamal M
J Gynecol Oncol; 2023 Sep; 34(5):e74. PubMed ID: 37668079
[TBL] [Abstract] [Full Text] [Related]
19. Assessing the Genomic Landscape of cervical cancers: Clinical Opportunities and Therapeutic Targets.
Friedman CF; Ravichandran V; Miller K; Vanderbilt C; Zhou Q; Iasonos A; Vivek M; Mishra P; Leitao MM; Broach V; Sonoda Y; Kyi C; Zamarin D; O'Cearbhaill RE; Konner J; Berger MF; Weigelt B; Momeni Boroujeni A; Park KJ; Aghajanian C; Solit DB; Donoghue MTA
Clin Cancer Res; 2023 Nov; 29(22):4660-4668. PubMed ID: 37643132
[TBL] [Abstract] [Full Text] [Related]
20. Knockdown of miR-24 Suppressed the Tumor Growth of cervical Carcinoma Through Regulating PTEN/pi3k/AKT Signaling Pathway.
He H; Lin C; Lu Y; Wu H
Biochem Genet; 2024 Apr; 62(2):1277-1290. PubMed ID: 37589947
[TBL] [Abstract] [Full Text] [Related]
[Next]
